Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) announced three accepted abstracts for oral and poster presentations at the International Liver Congress 2022, taking place June 22-26. The oral presentation will focus on Phase 2 trial data for VIR-2218, a potential functional cure for chronic hepatitis B virus (HBV) infection. Additionally, one poster will discuss dose-dependent durability from a Phase 1 trial of VIR-3434, while another will present preclinical data on the combination therapy of VIR-2218 and VIR-3434. These developments highlight the company's commitment to addressing the global health challenge posed by HBV.
Vir Biotechnology (Nasdaq: VIR) will host its 2022 Annual General Meeting (AGM) on May 20, 2022, at 11:30 a.m. PT, in a virtual format. Stockholders of record as of March 28, 2022, can participate by accessing the meeting via a provided online link. The virtual access will open at 11:15 a.m. PT. Investors are encouraged to vote and submit proxies ahead of the meeting, utilizing instructions from the proxy materials. Vir focuses on immunologic treatments for infectious diseases, including COVID-19 and hepatitis.
Vir Biotechnology reported significant financial results for Q1 2022, with $1.2 billion in collaboration revenue driven by sotrovimab distribution. The company's cash reserves exceeded $2.5 billion, ensuring adequate funding for upcoming clinical trials targeting COVID-19, hepatitis B, hepatitis D, and influenza. Encouraging initial data from the MARCH trial suggests promising efficacy of VIR-2218 and VIR-3434 in treating hepatitis B. However, the FDA de-authorized sotrovimab's use in the U.S. due to the Omicron BA.2 variant's prevalence.
Vir Biotechnology announced a virtual R&D Day focusing on its hepatitis B and D pipeline, scheduled for April 27, 2022, at 12:00 pm ET. The company will present initial data from the MARCH trial for treatment combinations of VIR-2218 and VIR-3434, reporting no drug-related safety signals. Additionally, a new program for chronic hepatitis D will be introduced. Key milestones for 2022 include further data on various trials for hepatitis B treatments. The company emphasizes a strong commitment to addressing the urgent public health challenges posed by chronic hepatitis B and D.
Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q1 2022 on May 5, 2022, after market close. Investors can access the results via a press release on the Vir website. The company focuses on immunologic therapies against infectious diseases, utilizing advanced technologies to boost the immune response. Its product pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (Nasdaq: VIR) will host a virtual Hepatitis Portfolio R&D Day on April 27, 2022, from 12:00 – 2:00 p.m. ET. The event aims to showcase the company's hepatitis pipeline and clinical advancements for 2022. Key presentations will be made by senior leaders, including George Scangos, Phil Pang, and Carey Hwang, along with a hepatitis treatment overview by Dr. Jordan Feld. Participants can register and access a live webcast on Vir's website, which will be available for 30 days post-event.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its scientists won the Pediatric COVID-19 Data Challenge, organized by BARDA and HHS. They developed a machine learning model to identify severe outcomes in pediatric COVID-19 patients using a dataset from over 116,000 pediatric outpatients. The award included a $200,000 prize, showcasing Vir’s commitment to leveraging AI for healthcare improvements. CEO George Scangos highlighted the significance of this achievement in enhancing patient care and pandemic preparedness.
Vir Biotechnology, Inc. (Nasdaq: VIR) will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on April 11, 2022, at 11:00 a.m. ET. The conference will be held virtually, and investors can access a live webcast of the discussion on the Vir website under the Events & Presentations section. The recording will be available for 30 days. Vir Biotechnology focuses on leveraging immunologic insights and technology to combat serious infectious diseases, with a development pipeline that includes COVID-19, hepatitis B virus, influenza A, and HIV.
Vir Biotechnology and GlaxoSmithKline announced that the FDA amended the Emergency Use Authorization for sotrovimab, indicating its 500 mg dose is unlikely to work against the Omicron BA.2 variant. The companies are preparing data to support a higher dose and will engage with global health authorities. The FDA's update excludes sotrovimab in areas where infections are likely due to non-susceptible variants. Sotrovimab remains authorized in various countries, but its usage is limited based on variant susceptibility and hospitalizations related to COVID-19.
Vir Biotechnology will participate in a panel discussion on infectious diseases at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 10:30 a.m. ET. The event will be held virtually, and a live webcast can be accessed through the Investors section of the Vir website, where it will also be archived for 30 days.
Vir Biotechnology focuses on developing treatments for serious infectious diseases using innovative immunologic technologies. Its pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.